GlassScriptPhysician profile
Barbara M Wilmarth
NPI 1477582138
$9,536.00
in general payments reported to CMS, 2019-2025
23 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $1,740 · 2023: $1,061 · 2024: $3,443 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,698 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,698.12 |
| Education | $128.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,785.76 | 2022-2025 | |
| Mdd US Operations, LLC | $1,633.30 | 2021-2025 | Gocovri, Gocovri, Apokyn |
| Amneal Pharmaceuticals LLC | $1,128.65 | 2021-2025 | Rytary, Crexont, Ongentys |
| Acadia Pharmaceuticals INC | $1,034.76 | 2021-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $859.55 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $472.89 | 2022-2025 | Qelbree |
| Merz Pharmaceuticals, LLC | $348.28 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Sunovion Pharmaceuticals INC. | $314.88 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $268.75 | 2022-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $237.92 | 2021 | |
| Kyowa Kirin, INC. | $234.43 | 2021-2024 | Nourianz |
| Acorda Therapeutics, INC | $202.04 | 2021-2024 | Inbrija, Ampyra |
| Eisai INC. | $180.59 | 2024-2025 | |
| Revance Therapeutics, INC. | $157.73 | 2024 | Daxxify, Daxi |
| Abbott Laboratories | $138.58 | 2024-2025 | Infinity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $122.22 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $110.69 | 2023-2025 | Nuedexta, Rexulti |
| Lilly USA, LLC | $76.30 | 2022-2024 | Amyvid |
| Avion Pharmaceuticals | $67.08 | 2022 | |
| Boston Scientific Corporation | $64.87 | 2022-2023 | |
| Lundbeck LLC | $41.33 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $38.95 | 2021-2022 | |
| Corium, LLC | $16.45 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Wilmarth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.